Gastroenteritis
Recent clinical, regulatory, research and industry developments relating to this disease.
Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q3 2026.
- Q3 2026A Phase 1/2, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
- Q4 2026Reduction of Severity and Duration of Pediatric Gastroenteritis Through Amino Acid Fortified Oral Rehydration Therapy
- Q1 2027A Phase 3, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of Age
- Q2 2027A Randomized, Open-Label Study to Assess Pharmacokinetics of Xifaxan® 200 mg in Pediatric Subjects 6 to 11 Years of Age With Acute Diarrhea of Suspected Bacterial Etiology, and the Safety and Efficacy of Xifaxan® 200 mg Plus Oral Rehydration Therapy (ORT) Compared to ORT Alone
Clinical MilestonesViewHide
- 2026-05-13A Phase 3, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of AgeResults expected Q1 2027
- 2026-04-03A Phase 1/2, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of AgeResults expected Q3 2026
- 2026-03-18A Randomized, Open-Label Study to Assess Pharmacokinetics of Xifaxan® 200 mg in Pediatric Subjects 6 to 11 Years of Age With Acute Diarrhea of Suspected Bacterial Etiology, and the Safety and Efficacy of Xifaxan® 200 mg Plus Oral Rehydration Therapy (ORT) Compared to ORT AloneResults expected Q2 2027
- 2026-02-12Reduction of Severity and Duration of Pediatric Gastroenteritis Through Amino Acid Fortified Oral Rehydration TherapyResults expected Q4 2026
- 2026-07-01The ORVAC Trial: A Phase IV, Double-blind, Randomised, Placebo-controlled Clinical Trial of a Third Scheduled Dose of RV1 Rotavirus Vaccine in Australian Indigenous Infants to Improve Protection Against GastroenteritisPrimary completion
- 2026-06-15Evaluating the Immunogenicity and Safety of the Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) in Healthy Infants Via a Randomized, Double-blind, Active-controlled Phase II Clinical Trial.Primary completion
- 2026-02-27The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants.Completed
- 2026-07-01ClinicalThe ORVAC Trial: A Phase IV, Double-blind, Randomised, Placebo-controlled Clinical Trial of a Third Scheduled Dose of RV1 Rotavirus Vaccine in Australian Indigenous Infants to Improve Protection Against GastroenteritisPrimary completion
- 2026-06-15ClinicalEvaluating the Immunogenicity and Safety of the Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) in Healthy Infants Via a Randomized, Double-blind, Active-controlled Phase II Clinical Trial.Primary completion
- 2026-05-13ClinicalA Phase 3, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of AgeResults expected Q1 2027
- 2026-04-03ClinicalA Phase 1/2, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of AgeResults expected Q3 2026
- 2026-03-18ClinicalA Randomized, Open-Label Study to Assess Pharmacokinetics of Xifaxan® 200 mg in Pediatric Subjects 6 to 11 Years of Age With Acute Diarrhea of Suspected Bacterial Etiology, and the Safety and Efficacy of Xifaxan® 200 mg Plus Oral Rehydration Therapy (ORT) Compared to ORT AloneResults expected Q2 2027
- 2026-02-27ClinicalThe Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants.Completed
- 2026-02-12ClinicalReduction of Severity and Duration of Pediatric Gastroenteritis Through Amino Acid Fortified Oral Rehydration TherapyResults expected Q4 2026
- 2025-10-21ClinicalA Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Subjects With Eosinophilic GastroenteritisResults posted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Foodborne Diseases2
- Gastroenteritis2
- Campylobacter1
- Campylobacter Infections1
- Communicable Diseases1
- COVID-191
- Immune Checkpoint Inhibitors1
- Neoplasms1
Leading journals4
- Epidemiology and infection2
- Frontiers in immunology1
- PLoS computational biology1
- The New England journal of medicine1
Leading researchers8
- Adegboye O1
- Amant F1
- Baarslag MA1
- Barone M1
- Beijnen JH1
- Borgers JSW1
- Buitelaar PLM1
- Castellanos ME1
Affiliations (unnormalised)6
- Amalia Children's Hospital1
- Australian Institute of Tropical Health and Medicine1
- Australian National University1
- Centre for Infectious Disease Control1
- Centre for Mathematical and Computational Biology1
- College of Public Health1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Gastroenteritis is inflammation of any part of the gastrointestinal tract, extending from the esophagus to the rectum. The supplied grounding indicates that it can arise from multiple causes, including infection, genetic factors, hypersensitivity, drug effects, and cancer.
The MeSH definition identifies several etiologic categories for gastroenteritis: genetic causes, infection, hypersensitivity, drug effects, and cancer. The review material also supports infectious gastroenteritis associated with food-borne bacterial pathogens such as Salmonella, Shigella, Campylobacter, Vibrio, and Listeria species.
Gastroenteritis involves inflammatory changes in the gastrointestinal tract. The supplied review material further supports an immunologic component in gut inflammation, including interactions between the intestinal microbiota, probiotics, and host immune homeostasis.
The grounding supports infection as a major risk factor or cause, including exposure to food-borne bacterial pathogens such as Salmonella, Shigella, Campylobacter, Vibrio, and Listeria species. It also supports environmental conditions associated with higher incidence of infectious gastroenteritis, including ambient temperature and precipitation.
The supplied grounding only supports that gastroenteritis is covered in the literature under drug therapy and diagnosis, but it does not provide enough detail to identify specific treatment classes. Based on the available material, standard management cannot be stated beyond general treatment-oriented and diagnostic evaluation contexts.
AI-generated summary grounded in MeSH and 2 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.